Briefing
Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)
A tumor-informed assay detected baseline ctDNA in 42/43 evaluable patients with locally advanced SCCHN; post-treatment positivity (4/42) predicted worse recurrence-free and overall survival, with a median lead time of 7.0 months.
- Design: Evidence level 3
- Assay: Not named in the abstract